From the Journals

Pericardial fat an independent risk factor for heart failure


 

Pericardial fat is associated with a heightened risk for heart failure, particularly in women, new research suggests.

In a prospective cohort study of nearly 7,000 individuals, excess pericardial fat was linked to a higher risk for heart failure, even after adjustment for established risk factors for heart failure.

Women with high pericardial fat volume (PFV), defined as more than 70 cm3 or 2.4 fluid ounces, had double the risk of developing heart failure. For men, high PFV, defined as more than 120 cm3 or 4.0 fluid ounces, was associated with a 50% increase in the risk for heart failure.

The findings were published in the Journal of the American College of Cardiology.

“People will ask why should they measure fat around the heart. Why can’t they just take the waist circumference or body mass index as a measure for increased risk?” lead author Satish Kenchaiah, MD, MPH, Icahn School of Medicine at Mount Sinai, New York, said in an interview.

“Yet, when we adjusted for waist circumference, hip circumference, waist to hip ratio, and other known variables, pericardial fat was still associated with an increased risk of heart failure. This tells me that it is not just overall fat in the body but something about its location around the heart that is playing a role,” Dr. Kenchaiah said.

“Now that we have found an association between any amount of fat around the pericardium and heart failure, it gives us an impetus to build future research on identifying how exactly these fat deposits influence the development of cardiomyopathy,” he said.

Dr. Kenchaiah and colleagues investigated the association of pericardial fat with incident heart failure by examining chest CT scans from 6,785 participants (3,584 women and 3,201 men aged 45-84 years) in the Multi-Ethnic Study of Atherosclerosis.

The participants were from four different ethnic groups: 38% were White; 28% were Black, 22% were Hispanic, and 12% were Chinese American. They were recruited between July 17, 2000, and Aug. 31, 2002, from six communities in the United States: Baltimore and Baltimore County; Chicago; Forsyth County, N.C.; Los Angeles County northern Manhattan and the Bronx, New York; and St. Paul, Minn.

All participants were free of cardiovascular disease at baseline.

The researchers followed participants for more than 17 years. During this time, 385 (5.7%; 164 women and 221 men) developed newly diagnosed heart failure.

In women, the hazard ratio for every 42 cm3 increase in PFV was 1.44 (95% confidence interval, 1.21-1.71; P < .001). In men, the HR was 1.13 (95% CI, 1.01-1.27; P = .03).

High PVF conferred a twofold greater risk for heart failure in women (HR, 2.06; 95% CI, 1.48-2.87; P < .001) and a 53% higher risk in men (HR, 1.53; 95% CI, 1.13-2.07; P = .006).

These associations remained significant after further adjustment for circulating markers of systemic inflammation (that is, C-reactive protein and interleukin-6), and abdominal subcutaneous or visceral fat.

They also found that the heightened risk persisted, even after adjustment for established risk factors for heart failure, such as age, cigarette smoking, alcohol consumption, sedentary lifestyle, high blood pressure, high blood sugar, high cholesterol, and myocardial infarction.

Results were similar among all of the ethnic groups studied.

Pages

Recommended Reading

FDA blazes path for ‘real-world’ evidence as proof of efficacy
MDedge Endocrinology
ACC 21 looks to repeat success despite pandemic headwinds
MDedge Endocrinology
PARADISE-MI: Sacubitril/valsartan can’t beat ramipril in patients with acute MI
MDedge Endocrinology
Dapagliflozin misses as treatment for COVID-19 but leaves intriguing signal for benefit
MDedge Endocrinology
FIDELIO-DKD: Finerenone cuts new-onset AFib in patients with type 2 diabetes and CKD
MDedge Endocrinology
Sotagliflozin’s HFpEF benefit confirmed by new analyses
MDedge Endocrinology
AHA reassures myocarditis rare after COVID vaccination, benefits overwhelm risks
MDedge Endocrinology
New AHA/ASA guideline on secondary stroke prevention
MDedge Endocrinology
Heart benefits of DASH low-sodium diet ‘swift and direct’
MDedge Endocrinology
Semaglutide boosts weight loss following endoscopic gastroplasty
MDedge Endocrinology